-
Ask
Send a request; the answer is not assumed.
-
Clinical review
A licensed U.S. clinician reads each request; some are declined.
-
If appropriate
Prescription-only care at mypromise.com: Promise Peptides prescribes PT-141 (bremelanotide) today.
Only U.S. patients enter this route; the patient's state and requested treatment set its limits. A formulation made by compounding has no FDA approval.
Appetite, in the plural · Peptide Biologicals
Wanting sex, wanting food, sending a growth signal: the biology gets interesting when those responses pull apart.
On desire, hunger and growth.
The bremelanotide reward experiment
I'd lazily tucked desire and pleasure into the same mental drawer. A bremelanotide experiment in female Syrian hamsters disrupted that comfortable arrangement: the drug did not enhance sexual reward in the test, and it did not change melanocortin-receptor gene expression in the reward circuitry examined. A desire drug, an animal experiment, an absent reward effect. That combination deserved an explanation.
The human studies asked different questions. In two trials involving 1,267 premenopausal women with hypoactive sexual desire disorder, bremelanotide improved measured desire and reduced distress about low desire over 24 weeks. Those women supplied the answers about desire; the hamsters supplied an answer about reward in an animal model. The experiments leave room for a more interesting account than an all-purpose switch for pleasure.
Hunger and fullness
Biologicals suggests living systems to me, with all their inconvenient specificity. Appetite is a useful way into them. Sexual interest, the urge to eat and the signals involved in growth share a vocabulary of wanting, yet the experiments measure very different things.
For semaglutide, STEP 1 measured body-weight change in adults with overweight or obesity without diabetes. People also describe fewer intrusive thoughts about food. Those descriptions are anecdotal, with no controlled clinical measurement behind them; I value the question they raise about the experience of hunger without treating them as another trial result. The semaglutide page starts with its amino-acid structure and follows the molecule towards fullness, weight and other clinical outcomes.
Ghrelin and growth
Ipamorelin activates the receptor used by ghrelin, a hormone involved in hunger. Its early experiments in rat pituitary cells, rats and swine established selective growth-hormone release. That is a striking response for such a short peptide. Translating it into a claim about a stronger or leaner person takes evidence the hormone measurement cannot supply.
I like this untidiness. The body can release a hormone, change its interest in food, or report a change in desire; each is an event worth understanding on its own terms. Ipamorelin research follows the growth signal, PT-141 returns to desire, and tirzepatide puts the appetite story beside a direct drug comparison. The comparison brings their different endpoints together without declaring a winner across unrelated conditions.